RecruitingEarly Phase 1NCT05543954

68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients

A Pilot Study of 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients

Sponsor

Peking Union Medical College Hospital

Enrollment

60 participants

Start Date

Sep 3, 2022

Study Type

INTERVENTIONAL

Conditions

Lung Neoplasms

Summary

Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. Lung cancer tissues express fibroblast activating protein FAP, and also have high expression of integrin αVβ3 receptor on the surface of blood vessels. In this study, a novel dual-target imaging agent 68Ga-FAPI-RGD was used for PET/CT imaging of lung cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of PET/CT scan using a tracer called 68Ga-FAPI-RGD, which is designed to light up cancer cells more precisely than standard scans. By comparing this new tracer to existing tracers (like standard FDG-PET), researchers hope to improve imaging accuracy for lung cancer diagnosis, staging, and treatment planning. **You may be eligible if:** - You have confirmed or suspected lung cancer - You are willing to undergo two PET/CT scans within 2 weeks (one with the new tracer and one with a standard tracer) - You are able to give written informed consent **You may NOT be eligible if:** - You are pregnant - You are breastfeeding - You have any medical condition that the doctor believes would significantly interfere with your safe participation in the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68Ga-FAPI-RGD

Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.

DRUG18F-FDG

Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg.

DRUG68Ga-FAPI

Intravenous injection of 68Ga-FAPI with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.

DRUG68Ga-RGD

Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.

Locations(1)

Peking Union Medical College Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05543954

Related Trials

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT074762873 locations

MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients

NCT075093331 location

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

NCT072919211 location

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

NCT071431102 locations

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

NCT071091547 locations